$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022012614 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$74.00K	$72.00K
YoY Change	2.78%	5.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.940M	$2.235M
YoY Change	76.29%	50.4%
% of Gross Profit
Research & Development	$7.208M	$3.279M
YoY Change	119.82%	21.18%
% of Gross Profit
Depreciation & Amortization	$31.00K	$119.0K
YoY Change	-73.95%	0.0%
% of Gross Profit
Operating Expenses	$11.15M	$5.514M
YoY Change	102.18%	31.54%
Operating Profit	-$11.07M	-$5.442M
YoY Change	103.49%	31.96%
Interest Expense	$130.0K	$260.0K
YoY Change	-50.0%	550.0%
% of Operating Profit
Other Income/Expense, Net	$81.00K	$263.0K
YoY Change	-69.2%	-8866.67%
Pretax Income	-$10.99M	-$5.180M
YoY Change	112.22%	26.65%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$10.99M	-$5.179M
YoY Change	112.26%	26.66%
Net Earnings / Revenue	-14855.41%	-7193.06%
Basic Earnings Per Share	-$0.25	-$0.14
Diluted Earnings Per Share	-$0.25	-$0.14
COMMON SHARES
Basic Shares Outstanding	43.23M shares	37.16M shares
Diluted Shares Outstanding	43.23M shares	37.16M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.5M	$125.6M
YoY Change	-8.87%	1250.54%
Cash & Equivalents	$20.05M	$14.66M
Short-Term Investments	$94.41M	$110.9M
Other Short-Term Assets	$5.997M	$2.700M
YoY Change	122.11%	200.0%
Inventory
Prepaid Expenses	$5.997M	$2.744M
Receivables	$447.0K	$242.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$135.8M	$128.6M
YoY Change	5.63%	1150.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$550.0K	$504.0K
YoY Change	9.13%	-33.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$188.0K	$238.0K
YoY Change	-21.01%	52.2%
Total Long-Term Assets	$3.398M	$1.003M
YoY Change	238.78%	-34.55%
TOTAL ASSETS
Total Short-Term Assets	$135.8M	$128.6M
Total Long-Term Assets	$3.398M	$1.003M
Total Assets	$139.2M	$129.6M
YoY Change	7.43%	996.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.261M	$803.0K
YoY Change	57.04%	34.06%
Accrued Expenses	$4.738M	$2.999M
YoY Change	57.99%	-12.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.664M	$4.479M
YoY Change	48.78%	-8.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.438M	$191.0K
YoY Change	1176.44%	37.37%
Total Long-Term Liabilities	$2.438M	$191.0K
YoY Change	1176.44%	37.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.664M	$4.479M
Total Long-Term Liabilities	$2.438M	$191.0K
Total Liabilities	$9.102M	$4.756M
YoY Change	91.38%	-16.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$270.8M	-$236.7M
YoY Change	14.42%	11.12%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%	-53.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$130.1M	$124.8M
YoY Change
Total Liabilities & Shareholders Equity	$139.2M	$129.6M
YoY Change	7.43%	996.64%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$10.99M	-$5.179M
YoY Change	112.26%	26.66%
Depreciation, Depletion And Amortization	$31.00K	$119.0K
YoY Change	-73.95%	0.0%
Cash From Operating Activities	-$10.25M	-$5.884M
YoY Change	74.18%	74.39%
INVESTING ACTIVITIES
Capital Expenditures	$171.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$18.53M	-$111.7M
YoY Change	-116.59%
Cash From Investing Activities	$18.36M	-$111.7M
YoY Change	-116.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	$1.263M
YoY Change	-100.0%	-48.57%
NET CHANGE
Cash From Operating Activities	-$10.25M	-$5.884M
Cash From Investing Activities	$18.36M	-$111.7M
Cash From Financing Activities	$0.00	$1.263M
Net Change In Cash	$8.109M	-$116.3M
YoY Change	-106.97%	12570.92%
FREE CASH FLOW
Cash From Operating Activities	-$10.25M	-$5.884M
Capital Expenditures	$171.0K	$0.00
Free Cash Flow	-$10.42M	-$5.884M
YoY Change	77.09%	74.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35558
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270809000	USD
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2022Q1	dei	City Area Code CityAreaCode	858
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	952-7570
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2022Q1	dei	Trading Symbol TradingSymbol	CRDF
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43306061	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20052000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11943000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	109310000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	128878000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4738000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4527000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	447000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	535000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5997000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4771000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	135806000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	146127000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	550000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2660000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2796000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	188000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	239000	USD
CY2022Q1	us-gaap	Assets Assets	139204000	USD
CY2021Q4	us-gaap	Assets Assets	149544000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1261000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1439000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	665000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	551000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6664000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6559000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2438000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2568000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	9102000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	9127000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41964000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43306000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43306000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41964000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	401655000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400503000	USD
CY2022Q1	crdf	Service Receivable ServiceReceivable	0	USD
CY2021Q4	crdf	Service Receivable ServiceReceivable	139000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-748000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-142000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259810000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	130102000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	139204000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149544000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	72000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7208000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3279000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3940000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2235000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	11148000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	5514000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11074000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5442000	USD
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	130000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	263000	USD
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021Q1	us-gaap	Interest Income Operating InterestIncomeOperating	57000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	207000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-49000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10999000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5185000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-67000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-606000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43231000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43231000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37164000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37164000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11599000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5246000	USD
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2022Q1	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-11605000	USD
CY2021Q1	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-5252000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1152000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-606000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1000	USD
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	USD
CY2022Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	139000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	130102000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128158000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	268000	USD
CY2021Q1	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1263000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-67000	USD
CY2021Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	USD
CY2021Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	380000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	124817000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1141000	USD
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	119000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1152000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	268000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-346000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-204000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	207000	USD
CY2022Q1	crdf	Release Of Clinical Trial Funding Commitment For Services Received ReleaseOfClinicalTrialFundingCommitmentForServicesReceived	139000	USD
CY2021Q1	crdf	Release Of Clinical Trial Funding Commitment For Services Received ReleaseOfClinicalTrialFundingCommitmentForServicesReceived	380000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-51000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-166000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-88000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-79000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	183000	USD
CY2022Q1	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-136000	USD
CY2021Q1	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-82000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1421000	USD
CY2022Q1	crdf	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16000	USD
CY2021Q1	crdf	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-227000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-42000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	34000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10249000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5884000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	171000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	38217000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	36773000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	114195000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	17085000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2497000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18358000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111698000	USD
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1263000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1263000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8109000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-116319000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11943000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130981000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20052000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14662000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	27000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2022Q1	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6000	USD
CY2021Q1	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	129400000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11300897	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9025380	shares
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	94906000	USD
CY2022Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	5000	USD
CY2022Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	501000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	94410000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	15152000	USD
CY2022Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	0	USD
CY2022Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	252000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	14900000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	110058000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	6000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	65000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	753000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	109310000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	95643000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95584000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	33377000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	1000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	84000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	33294000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	129020000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	149000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	128878000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3441000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4022000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3823000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3472000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	550000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	878000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1435000	USD
CY2022Q1	crdf	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	420000	USD
CY2021Q4	crdf	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	414000	USD
CY2022Q1	crdf	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2022Q1	crdf	Accrued Clinical Trial AccruedClinicalTrial	2110000	USD
CY2021Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	1639000	USD
CY2022Q1	crdf	Accrued Research Agreements AccruedResearchAgreements	992000	USD
CY2021Q4	crdf	Accrued Research Agreements AccruedResearchAgreements	726000	USD
CY2022Q1	crdf	Accrued Director Fees AccruedDirectorFees	141000	USD
CY2021Q4	crdf	Accrued Director Fees AccruedDirectorFees	141000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	53000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	63000	USD
CY2022Q1	crdf	Patent License And Other Fees Payable PatentLicenseAndOtherFeesPayable	75000	USD
CY2021Q4	crdf	Patent License And Other Fees Payable PatentLicenseAndOtherFeesPayable	43000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	69000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	66000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4738000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4527000	USD
CY2022Q1	crdf	Lessee Operating Lease Area Of Lease LesseeOperatingLeaseAreaOfLease	12300	sqft
CY2022Q1	crdf	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	60000	USD
CY2022Q1	crdf	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2022Q1	crdf	Lessor Area Of Sublease LessorAreaOfSublease	16600	sqft
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	191000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	95000	USD
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	0	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	101000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	191000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	-6000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2660000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2796000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2438000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2568000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	665000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	551000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3103000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3119000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	70000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	240000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	480000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	737000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	754000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	775000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	796000	USD
CY2022Q1	crdf	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	137000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3679000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	576000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3103000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1152000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	268000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	24000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2021Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
CY2021	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2022Q1	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
CY2022Q1	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y8M12D

Files In Submission

Name	View Source	Status
0001628280-22-012614-index-headers.html	Edgar Link	pending
0001628280-22-012614-index.html	Edgar Link	pending
0001628280-22-012614.txt	Edgar Link	pending
0001628280-22-012614-xbrl.zip	Edgar Link	pending
crdf-033122exhibit311.htm	Edgar Link	pending
crdf-033122exhibit312.htm	Edgar Link	pending
crdf-033122exhibit321.htm	Edgar Link	pending
crdf-033122exhibit322.htm	Edgar Link	pending
crdf-20220331.htm	Edgar Link	pending
crdf-20220331.xsd	Edgar Link	pending
crdf-20220331_cal.xml	Edgar Link	unprocessable
crdf-20220331_def.xml	Edgar Link	unprocessable
crdf-20220331_htm.xml	Edgar Link	completed
crdf-20220331_lab.xml	Edgar Link	unprocessable
crdf-20220331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2022 Q1 Form 10-Q Financial Statement

#000162828022012614 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2022 Q1 Form 10-Q Financial Statement

#000162828022012614 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf